Trial Profile
A phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractroy B-Cell NHL [non-Hodgkin's lymphoma]/L3ALL [acute lymphoblastic leukaemia]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 02 Nov 2005 New trial record.